Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Barinthus Biotherapeutics (BRNS) Receivables Refunds (2020 - 2023)

Barinthus Biotherapeutics filings provide 4 years of Receivables Refunds readings, the most recent being $1.7 million for Q3 2023.

  • On a quarterly basis, Receivables Refunds rose 17090.0% to $1.7 million in Q3 2023 year-over-year; TTM through Sep 2023 was $1.7 million, a 17090.0% increase, with the full-year FY2021 number at $705000.0, up 131.15% from a year prior.
  • Receivables Refunds hit $1.7 million in Q3 2023 for Barinthus Biotherapeutics, up from $10000.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $1.7 million in Q3 2023 to a low of $10000.0 in Q3 2022.
  • Median Receivables Refunds over the past 4 years was $305000.0 (2020), compared with a mean of $496444.4.
  • Biggest five-year swings in Receivables Refunds: crashed 94.28% in 2022 and later soared 17090.0% in 2023.
  • Barinthus Biotherapeutics' Receivables Refunds stood at $305000.0 in 2020, then skyrocketed by 131.15% to $705000.0 in 2021, then crashed by 98.58% to $10000.0 in 2022, then soared by 17090.0% to $1.7 million in 2023.
  • The last three reported values for Receivables Refunds were $1.7 million (Q3 2023), $10000.0 (Q3 2022), and $1.0 million (Q2 2022) per Business Quant data.